Navigation Links
CASTLE Study Showed Similar Efficacy Between Once-Daily REYATAZ(R) (atazanavir sulfate)/ritonavir and Twice-Daily lopinavir/ritonavir at 48 Weeks in Previously Untreated HIV-Infected Adult Patients
Date:2/6/2008

in the once-daily REYATAZ(R) (atazanavir sulfate)/r arm or the twice-daily lopinavir/r arm were diarrhea (two percent and eleven percent, respectively) nausea (four percent and eight percent, respectively), jaundice (four percent and zero percent, respectively) and rash (three percent and two percent, respectively).

The REYATAZ/r arm was associated with significantly lower increases from baseline compared to the lopinavir/r arm in total cholesterol, triglycerides and non-HDL cholesterol at 48 weeks (p<0.0001). Two percent of patients in the REYATAZ/r arm and seven percent of patients in the lopinavir/r arm required initiation of lipid-lowering therapy in the study.

Safety events in this study were consistent with prior experience. Four deaths were reported in each treatment arm at 48 weeks; none were attributed to the study medications. Twelve percent of patients in the REYATAZ/r arm and ten percent of patients in the lopinavir/r arm experienced a serious adverse event.

Nine percent of patients in the REYATAZ/r arm and thirteen percent of patients in the lopinavir/r arm discontinued the study therapy before week 48.

About the CASTLE Study

The international, multi-center, open-label, 96-week CASTLE study randomized 883 treatment-naive patients infected with HIV-1. Four hundred and forty patients were randomized to receive REYATAZ 300 mg and ritonavir 100 mg once daily and 443 patients were randomized to receive lopinavir 400 mg and ritonavir 100 mg twice daily, each in combination with a once-daily, fixed- dose combination of emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg. All patients had a baseline viral load of greater than or equal to 5,000 copies/mL; there was no CD4+ cell count restriction for study entry. The primary endpoint for the study was the proportion of patients with viral load of less than 50 copies/mL at 48 weeks.

Additional Study Results

A number of secondary endpoints were also measured w
'/>"/>

SOURCE Bristol-Myers Squibb Company
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Joslin Study Identifies Key Factor That Links Metabolic Syndrome; Finding May Help Millions at High Risk of Cardiovascular Disease
2. Ceremeds OSTENE(R) Stops Bone Bleeding Without Added Risk of Surgical Infection, New Study Finds
3. IDM Pharma Announces Phase 3 Mifamurtide (L-MTP-PE) Study Demonstrating Improved Survival Published in the Journal of Clinical Oncology
4. Tigris Pharmaceuticals Initiates Phase I Study of AFP-464 in Patients with Solid Tumors
5. Inverseon Announces Positive Phase IIa Asthma Study
6. Takeda Doses First Patient in a U.S. Phase 1 Study of Hematide(TM) to Treat Chemotherapy Induced Anemia
7. Study Says Allergy Shots Help Children, Reduce Health Care Costs
8. EntreMed Commences Phase 2 Study With MKC-1 in Ovarian/Endometrial Cancers
9. Mayo Clinic Study Finds Further Association Between Diabetes and Pancreatic Cancer
10. Divine Corporations Personal Lubricants Shown to Block Cancer-causing Viruses in a Study by the National Cancer Institute
11. Protalix BioTherapeutics Extends Research Agreement With Yissum Based on Promising Acetylcholinesterase Program Results in Animal Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/17/2014)... DALLAS , September 17, 2014 ... Electronics Market by Component (Sensor, Battery, Memory Device, Display, ... and Fitness & Wellness), and by Geography - Global ... of medical electronics market is expected to reach $56.50 ... from 2014 to 2020. Browse 235 market ...
(Date:9/17/2014)... , Sept. 17, 2014  NuView Life Sciences, ... licensing and collaboration agreement with Otsuka Pharmaceutical Co., ... investigative genomic-based diagnostic biomarker to detect cancers of ... all other future diagnostic-imaging applications. NuView retains all ... delivery and in-vitro urine screen applications. ...
(Date:9/17/2014)... 17, 2014 Isis Pharmaceuticals, Inc. (NASDAQ: ... earned a $4 million milestone payment from Achaogen, ... the initiation of a Phase 3 study of ... gram-negative bacterial infections.  The Phase 3 study is ... efficacy and safety of plazomicin compared to colistin ...
Breaking Medicine Technology:Medical Electronics Market Worth $56.50 Billion by 2020 2Medical Electronics Market Worth $56.50 Billion by 2020 3Medical Electronics Market Worth $56.50 Billion by 2020 4NuView Life Sciences Enters Global Licensing Agreement With Otsuka Pharmaceutical 2NuView Life Sciences Enters Global Licensing Agreement With Otsuka Pharmaceutical 3NuView Life Sciences Enters Global Licensing Agreement With Otsuka Pharmaceutical 4NuView Life Sciences Enters Global Licensing Agreement With Otsuka Pharmaceutical 5Isis Pharmaceuticals Earns $4 Million from Achaogen for the Initiation of a Phase 3 Study of Plazomicin 2Isis Pharmaceuticals Earns $4 Million from Achaogen for the Initiation of a Phase 3 Study of Plazomicin 3
... 2011 Promax Applications Group ( www.promaxtpo.com ), ... and optimization solutions, today announced that Kimberly-Clark Corporation ... Trade Promotion Management (TPM) and Optimization (TPO) solution ... the world,s most recognized consumer brands sold in ...
... Va., March 1, 2011 Health Diagnostic Laboratory ... its partnership to develop a novel laboratory developed ... venture developing diagnostic test and surgical therapy solutions ... disease (CVD), coronary heart disease (CHD) and stroke ...
Cached Medicine Technology:Kimberly-Clark Corporation Selects Promax as its North America Trade Promotion Management and Optimization Solution Provider 2Health Diagnostic Laboratory, Inc. (HDL, Inc.) Partners With Gamma Therapeutics to Offer Breakthrough Diagnostic Assay for Heart Attack and Stroke Risk 2Health Diagnostic Laboratory, Inc. (HDL, Inc.) Partners With Gamma Therapeutics to Offer Breakthrough Diagnostic Assay for Heart Attack and Stroke Risk 3
(Date:9/17/2014)... 2014 As kinship care continues to ... cannot live with their parents, emphasis on kinship care ... enhance services and supports for kinship caregivers and families. ... Kinship Care Conference is being held this week in ... practice, policy, program and service development for kinship caregivers, ...
(Date:9/17/2014)... reserved for the very healthy. Astronauts are selected ... and psychological standards to prepare them for any ... spaceflight, average people can now fly for enjoyment. ... information about what medical conditions or diseases should ... as most medical conditions have never been studied ...
(Date:9/17/2014)... (PRWEB) September 17, 2014 People who struggle ... now head to http://www.perwickstrom.com and get the answer ... thing to point out, is that a business plan and ... they work together, commented Per Wickstrom. “The way I view ... by a business strategy which is part two.” , ...
(Date:9/17/2014)... Bioluminescence, nanoparticles, gene manipulation these sound like ... in fact, they are components of an exciting ... In preclinical animal models of metastatic prostate cancer, ... VCU Institute of Molecular Medicine and Johns Hopkins ... molecular imaging approach that could revolutionize doctors, ability ...
(Date:9/17/2014)... September 17, 2014 Catalent Pharma ... technologies and development solutions for drugs, biologics and ... OptiPact™, an integrated service and technology offer based ... provided from the company’s 450,000 sq. ft. Kansas ... ability to integrate optimal formulation, development, analytical expertise, ...
Breaking Medicine News(10 mins):Health News:Arizona’s Children Association Kinship Service Providers Invited to Present at the CWLA National Conference 2Health News:Space: The final frontier… open to the public 2Health News:Per Wickstrom’s Latest Blog Explores the Difference Between a Business Plan and a Business Strategy 2Health News:New non-invasive technique could revolutionize the imaging of metastatic cancer 2Health News:New non-invasive technique could revolutionize the imaging of metastatic cancer 3Health News:New OptiPact™ Technology Introduced by Catalent 2
... IVIG worked. Its ability to treat autoimmune diseases seemed ... immunoglobulin (IVIG) is a complex mixture of IgG antibodies ... from thousands of people, and is only FDA-approved to ... it off-label with varied success in patients with lupus, ...
... geographic convenience and the quality of services that can ... to an article// in the latest edition of the ... a developing trend towards urban centralisation of surgical services, ... care standards. ,However, this creates geographical distances ...
... The Public Works and Government Services Canada said that there ... programs this year.// ,The vaccine instead of being ... in the month of November. Dr. Sheela Basrur, Ontario's chief ... by the beginning of the flu season. Public Works buys ...
... a study conducted by Prof Bernard a senior lecturer at ... found that more number// of rural people of heart attacks ... ,Statistics show that heart disease mortality rates in rural areas ... in women than in urban areas. But the solution to ...
... Australians who have type 2 diabetes could also be at ... the latest issue of the Medical Journal of Australia.// ... Renal Impairment cO-existing with NIDDM (non-insulin dependent diabetes mellitus) - ... ever undertaken in Australian general practice. ,NEFRON examined ...
... A study in Britain has found that nearly one-third of ... purpose, due to rupture, or simply slipping off// during sex, ... ,NOP world undertook a survey of nearly 497 people for ... nearly 64% were groping in the dark about the reasons ...
Cached Medicine News:Health News:Single Sugar Enables Antibody to Treat Inflammation 2Health News:Single Sugar Enables Antibody to Treat Inflammation 3Health News:Bolster Rural Surgical Services 2
The CGIL iridectomy contact glass was designed by Riquin, Fankhauser et al. to perform full thickness peripheral laser iridectomies....
The CGVL vitrectomy contact glass was designed by Rol, Fankhauser et al. for photodisruptive YAG laser procedures in the posterior vitreous....
For newly born children 10 mm internal diameter of the cornea part. Designed to work with argon/YAG Lasers....
... The HAAG-STREIT OM 900 Ophthalmometer uses ... the three requirements of Helmholtz: 1. The ... of the distance between the Ophthalmometer and ... are independent of the distance between the ...
Medicine Products: